Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation

I Kupfer-Bessaguet; G Guillet; L Misery; J L Carre; J P Leroy; Bruno Sassolas

doi:10.1016/j.jaad.2004.05.004

Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation

J Am Acad Dermatol. 2004 Oct;51(4):635-9. doi: 10.1016/j.jaad.2004.05.004.

Authors

I Kupfer-Bessaguet¹, G Guillet, L Misery, J L Carre, J P Leroy, Bruno Sassolas

Affiliation

¹ Department of Dermatology, Laboratory of Pathology, University Hospital Morvan, Brest, France.

PMID: 15389205
DOI: 10.1016/j.jaad.2004.05.004

Abstract

We have treated extensive lentigo maligna in two elderly patients with Imiquimod 5% (Aldara). It was applied 3 times weekly, for 3 to 5 months. Clinical and histological remission was observed over 13 months of follow-up care. Tolerance was good. We suggest that topical imiquimod could be an interesting therapeutic alternative.

Publication types

Case Reports

MeSH terms

Administration, Topical
Aged
Aged, 80 and over
Aminoquinolines / administration & dosage*
Antineoplastic Agents / administration & dosage*
Biopsy
Drug Administration Schedule
Female
Humans
Hutchinson's Melanotic Freckle / drug therapy*
Hutchinson's Melanotic Freckle / pathology*
Imiquimod
Male
Skin / pathology
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology*
Treatment Outcome

Substances

Aminoquinolines
Antineoplastic Agents
Imiquimod